Patents by Inventor Dominique Paul Michel Depré

Dominique Paul Michel Depré has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180093943
    Abstract: Disclosed is a process for the preparation of certain intermediates, e.g. those in the scheme below: which intermediates and processes are useful in the preparation of the macrocyclic HVC inhibitor Simeprevir.
    Type: Application
    Filed: March 25, 2016
    Publication date: April 5, 2018
    Applicant: Janssen Pharmaceuticals, Inc.
    Inventors: Dominique Paul Michel Depré, Dominic John Ormerod, Andras Horvath, Thomas Shaw Moody, Maude Brossat, Olivier Riant, Nicolas Vriamont, Sébastien Francois Emmanuel Lemaire, Sébastien Nicolas J. Hermant
  • Publication number: 20170152253
    Abstract: A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(?)-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-(?)-ephedrine from the precipitated salt obtained in step (b).
    Type: Application
    Filed: February 10, 2017
    Publication date: June 1, 2017
    Applicant: Janssen Pharmaceuticals, Inc.
    Inventors: Dominic John Ormerod, Dominique Paul Michel Depre, Andras Horvath
  • Patent number: 9586893
    Abstract: A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(?)-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-(?)-ephedrine from the precipitated salt obtained in step (b).
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: March 7, 2017
    Assignee: Janssen Pharmaceuticals
    Inventors: Dominic John Ormerod, Dominique Paul Michel Depre, Andras Horvath
  • Patent number: 9328108
    Abstract: The present invention relates to an improved process for preparing (2R,3aR,10Z,11aS,12aR,14aR)-cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5-methyl-4,14-dioxo-, ethyl ester. This compound is an intermediate in the overall synthesis route of the macrocyclic compound TMC 435. TMC 435 is an inhibitor of NS3/4A protease which plays an important role in the replication of the hepatitis C virus.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: May 3, 2016
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Andras Horvath, Stijn Wuyts, Dominique Paul Michel Depré, Wouter Louis J. Couck, Jozef Ludo Jan Cuypers, Syuzanna Harutyunyan, Gregory Fabien Sebastian Binot
  • Patent number: 9227965
    Abstract: Disclosed is a process for the preparation of a cinchonidine salt of formula (IV) via an aqueous solution of a racemic 4-hydroxy-1,2-cyclopentanedicarboxylic acid, which is subjected to cyclization without removing water, by the addition of a water-miscible organic solvent to the aqueous solution and, again without removing water, adding cinchonidine to the aqueous-organic solvent solution so as to obtain the cinchonidine salt of the lactone acid. The cinchonidine salt is allowd to crystallize so as to obtain the enantiomerically purified crystalline lactone acid cinchonidine salt (IV). The enantiomerically pure salt is an intermediate in the synthesis of HCV inhibitor compound of formula (I).
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: January 5, 2016
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Andras Horvath, Dominique Paul Michel Depré, Dominic John Ormerod
  • Patent number: 9115077
    Abstract: The present invention relates to the cinchonidine salt useful in the preparation of intermediates for preparing a macrocyclic HCV inhibitor, as well as processes involving this salt.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: August 25, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Andras Horvath, Dominic John Ormerod, Dominique Paul Michel Depre, Veronique Cerpentier
  • Publication number: 20150152098
    Abstract: The present invention relates to an improved process for preparing (2R,3aR,10Z,11aS,12aR,14aR)-cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5-methyl-4,14-dioxo-, ethyl ester. This compound is an intermediate in the overall synthesis route of the macrocyclic compound TMC 435. TMC 435 is an inhibitor of NS3/4A protease which plays an important role in the replication of the hepatitis C virus.
    Type: Application
    Filed: February 9, 2015
    Publication date: June 4, 2015
    Inventors: Andras Horvath, Stijn Wuyts, Dominique Paul Michel Depré, Wouter Louis J. Couck, Jozef Ludo Jan Cuypers, Syuzanna Harutyunyan, Gregory Fabien Sebastian Binot
  • Publication number: 20150141652
    Abstract: The present invention relates to an improved process for preparing 2-[(2E)-2-fluoro-2-(3-piperidinylidene)ethyl]-1H-isoindole-1,3(2H)-dione, or a salt thereof, which is an intermediate in the synthesis route of the antibacterial compound 7-[(3E)-3-(2-amino-1-fluoroethylidene)-1-piperidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo 3-quinolinecarboxylic acid.
    Type: Application
    Filed: September 28, 2012
    Publication date: May 21, 2015
    Applicant: Janssen Pharmaceutica NV
    Inventors: Yolande Lydia Lang, Dominique Paul, Michel Depre
  • Publication number: 20150080577
    Abstract: The present invention relates to the cinchonidine salt useful in the preparation of intermediates for preparing a macrocyclic HCV inhibitor, as well as processes involving this salt.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Inventors: Andras Horvath, Dominic John Ormerod, Dominique Paul Michel Depre, Veronique Cerpentier
  • Patent number: 8981082
    Abstract: The present invention relates to an improved process for preparing (2R,3aR,10Z,11aS,2aR,14aR)-cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-10(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5-methyl-4,14-dioxo-, ethyl ester. This compound is an intermediate in the overall synthesis route of the macrocyclic compound TMC 435. TMC 435 is an inhibitor of NS3/4A protease which plays an important role in the replication of the hepatitis C virus.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: March 17, 2015
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Andras Horvath, Stijn Wuyts, Dominique Paul Michel Depré, Wouter Louis J. Couck, Jozef Ludo Jan Cuypers, Syuzanna Harutyunyan, Gregory Fabien Sebastian Binot
  • Patent number: 8927722
    Abstract: The present invention relates to the cinchonidine salt useful in the preparation of intermediates for preparing a macrocyclic HCV inhibitor, as well as processes involving this salt.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: January 6, 2015
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Andras Horvath, Dominic John Ormerod, Dominique Paul Michel Depre, Veronique Cerpentier
  • Publication number: 20140235852
    Abstract: The present invention relates to an improved process for preparing (2R,3aR,10Z,11aS,2aR,14aR)-cyclopenta[c]cyc-lopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2[[7-methoxy-8-methyl-2-[4-10 (1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5-methyl-4,14-dioxo-, ethyl ester. This compound is an intermediate in the overall synthesis route of the macrocyclic compound TMC 435. TMC 435 is an inhibitor of NS3/4A protease which plays an important role in the replication of the hepatitis C virus.
    Type: Application
    Filed: October 26, 2012
    Publication date: August 21, 2014
    Applicant: Janssen Pharmaceuticals, Inc.
    Inventors: Andras Horvath, Stijn Wuyts, Dominique Paul Michel Depré, Wouter Louis J. Couck, Jozef Ludo Jan Cuypers, Syuzanna Harutyunyan, Gregory Fabien Sebastian Binot
  • Publication number: 20140228574
    Abstract: Disclosed is a process for the preparation of a cinchonidine salt of formula (IV) via an aqueous solution of a racemic 4-hydroxy-1,2-cyclopentanedicarboxylic acid, which is subjected to cyclization without removing water, by the addition of a water-miscible organic solvent to the aqueous solution and, again without removing water, adding cinchonidine to the aqueous-organic solvent solution so as to obtain the cinchonidine salt of the lactone acid. The cinchonidine salt is allowd to crystallize so as to obtain the enantiomerically purified crystalline lactone acid cinchonidine salt (IV). The enantiomerically pure salt is an intermediate in the synthesis of HCV inhibitor compound of formula (I).
    Type: Application
    Filed: September 21, 2012
    Publication date: August 14, 2014
    Inventors: Andras Horvath, Dominique Paul Michel Depré, Dominic John Ormerod
  • Patent number: 8722892
    Abstract: The present invention relates to synthesis procedures and intermediates of a compound of formula: and the salts thereof.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: May 13, 2014
    Assignee: Janssen R&D Ireland
    Inventors: Andras Horvath, Dominique Paul Michel Depre, Dominic John Ormerod
  • Publication number: 20130005976
    Abstract: A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(?)-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-(?)-ephedrine from the precipitated salt obtained in step (b).
    Type: Application
    Filed: March 16, 2011
    Publication date: January 3, 2013
    Applicant: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Dominic John Ormerod, Dominique Paul Michel Depre, Andras Horvath
  • Publication number: 20120238746
    Abstract: The present invention relates to synthesis procedures and intermediates of a compound of formula: and the salts thereof.
    Type: Application
    Filed: May 31, 2012
    Publication date: September 20, 2012
    Inventors: Andras Horvath, Dominique Paul Michel Depré, Dominic John Ormerod
  • Patent number: 8212043
    Abstract: The present invention relates to synthesis procedures and intermediates of a compound of formula: and the salts thereof.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: July 3, 2012
    Assignee: Janssen R&D Ireland
    Inventors: Andras Horvath, Dominique Paul Michel Depré, Dominic John Ormerod
  • Publication number: 20110257403
    Abstract: The present invention relates to the cinchonidine salt useful in the preparation of intermediates for preparing a macrocyclic HCV inhibitor, as well as processes involving this salt.
    Type: Application
    Filed: December 22, 2009
    Publication date: October 20, 2011
    Inventors: Andras Horvath, Dominic John Ormerod, Dominique Paul Michel Depre, Veronique Cerpentier
  • Publication number: 20100041889
    Abstract: The present invention relates to synthesis procedures and intermediates of a compound of formula: and the salts thereof.
    Type: Application
    Filed: February 1, 2008
    Publication date: February 18, 2010
    Inventors: Andras Horvath, Dominique Paul Michel Depré, Dominic John Ormerod